Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    "Richter syndrome"
Show Display Options
Rank Status Study
1 Active, not recruiting Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome
Condition: Richter's Syndrome
Intervention: Drug: Ofatumumab
2 Recruiting Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Conditions: Mediastinal Large B-cell Lymphoma;   Richter Syndrome
Intervention: Biological: Pembrolizumab
3 Terminated Selinexor in Initial or Relapsed/Refractory Richter's Transformation
Condition: Richter's Transformation
Intervention: Drug: selinexor
4 Terminated PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
Condition: Richter's Transformation
Intervention: Drug: PNT2258
5 Completed
Has Results
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
Conditions: Richter's Transformation;   Leukemia
Interventions: Drug: Oxaliplatin;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Rituximab;   Drug: Pegfilgrastim
6 Active, not recruiting ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Richter's Syndrome;   Prolymphocytic Leukemia
Intervention: Drug: ACP-196
7 Withdrawn Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation
Conditions: Prolymphocytic Leukemia;   Recurrent Mantle Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Richter Syndrome
Interventions: Drug: sotrastaurin acetate;   Other: pharmacological study;   Other: laboratory biomarker analysis
8 Recruiting Registry of the German CLL Study Group
Conditions: CLL;   SLL;   HCL;   Richter´s Transformation;   Leukemia, Prolymphocytic, B-Cell;   Leukemia, Prolymphocytic, T-Cell;   T-LGL Leukemia;   NK-LGL Leukemia
9 Recruiting Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Conditions: Recurrent Chronic Lymphocytic Leukemia;   Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Nodal Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Splenic Marginal Zone Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Nodal Marginal Zone Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Refractory Splenic Marginal Zone Lymphoma;   Richter Syndrome;   Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib;   Drug: Idelalisib;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
10 Active, not recruiting Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Alkylating Agent-Related Acute Myeloid Leukemia;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Hepatosplenic T-Cell Lymphoma;   Intraocular Lymphoma;   Lymphomatous Involvement of Non-Cutaneous Extranodal Site;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Nodal Marginal Zone Lymphoma;   Post-Transplant Lymphoproliferative Disorder;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Richter Syndrome;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   T-Cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Pharmacological Study
11 Recruiting ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Conditions: Non-hodgkin Lymphoma;   Multiple Myeloma;   Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Richter's Syndrome;   Waldenstrom Macroglobulinemia;   Myelofibrosis
Interventions: Drug: ACP-196;   Drug: Pembrolizumab
12 Completed
Has Results
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
Condition: Leukemia
Interventions: Drug: Cytarabine;   Drug: Fludarabine;   Drug: Oxaliplatin;   Drug: Rituximab
13 Completed VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
Conditions: Leukemia;   Lymphoma
Intervention: Drug: laromustine
14 Completed
Has Results
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Prolymphocyctic Leukemia;   Richter's Transformation
Interventions: Drug: PCI-32765;   Drug: ofatumumab
15 Completed Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate
16 Withdrawn Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
Conditions: Lymphoproliferative Malignancies;   Acute Myeloid Leukemia
Intervention: Drug: ZEN003365
17 Terminated
Has Results
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Intervention: Drug: 5-Azacytidine
18 Not yet recruiting Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
Condition: Hematologic Malignancy
Interventions: Drug: Fludarabine;   Drug: Cytarabine;   Drug: Erwinase

Indicates status has not been verified in more than two years